ArticleUpdates in surgery2024
The safety and efficacy of primary duct closure after laparoscopic common bile duct exploration in patients with mild-to-moderate calculus-associated acute cholangitis: a retrospective cohort study.
Article in Updates in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While laparoscopic common bile duct exploration with primary duct closure (LCBDE + PDC) has been considered a feasible and safe treatment for cholecystocholedocholithiasis, uncertainties remain regarding its effectiveness and safety in patients with mild-to-moderate calculus-associated acute cholangitis. Therefore, this study aims to investigate the safety and efficacy of LCBDE + PDC specifically in patients with mild-to-moderate acute cholangitis (AC). Patients with cholecystocholedocholithiasis who underwent LCBDE + PDC treatment at our hospital between July 2020 and September 2022 were included. The patients were divided into two groups based on the presence of cholangitis: acute cholangitis (AC group) and non-acute cholangitis (non-AC group). A total of 136 patients underwent LCBDE + PDC treatment, with 65 in the AC group and 71 in the non-AC group. No deaths occurred after surgery in either group. The AC group had longer drainage tube retention time (5 (4-7) days vs. 4 (3-5) days, P < 0.001), postoperative hospital stay (8 (6-9) days vs. 6 (5-7) days, P < 0.001), and total hospital stay (12 (9.5-15) days vs. 10 (8-13) days, P < 0.001) compared to the non-AC group. However, there were no significant differences between the two groups in terms of operation time, estimated blood loss, and the rate of using holmium laser lithotripsy. The incidence of postoperative complications was similar between the two groups. Our study demonstrates that LCBDE + PDC is a safe and feasible treatment for patients with mild-to-moderate calculus-associated acute cholangitis who meet the criteria for primary duct closure.
Indexed as
Identifiers
39581941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.